Skip to main content
. 2016 May 20;5(5):e003369. doi: 10.1161/JAHA.116.003369

Table 5.

Patient Groups Identified by Using CART Analysis

Patient Group Group Characteristics Possible Additional Risk Factors [% Patient Group] No. of Patients No. (%) of Adverse Events
Development Set Test Set Entire Dataset Development Set Test Set Entire Dataset
1 Neurodevelopmental condition(s) May also have:
Congenital anomalies [52%]
HLHS, UVH/PA+IVS [17%]
LOS >1 mo [26%]
192 115 307 53 (28%) 22 (19%) 75 (24%)
2 No neurodev. conditions
VSD/other
Congenital anomalies
LOS >1 mo
95 76 171 20 (21%) 21 (28%) 41 (24%)
3 No neurodev. conditions
HLHS, UVH/PA+IVS
May also have:
congenital anomalies [10%]
LOS >1 mo [20%]
524
HLHS=219
UVH/PA+IVS=305
344
HLHS=147
UVH/PA+IVS=197
868
HLHS=366
UVH/PA+IVS=502
82 (16%)
HLHS=37 (17%)
UVH/PA+IVS=45 (15%)
50 (15%)
HLHS=28 (19%)
UVH/PA+IVS=22 (11%)
132 (15%)
HLHS=65 (18%)
UVH/PA+IVS=67 (13%)
4 No neurodev. conditions
VSD/other
No congenital anomalies
LOS >1 mo
189 135 324 20 (11%) 10 (7%) 30 (9%)
5 No neurodev. conditions
VSD/other
Congenital anomalies
LOS <1 mo
701 494 1195 60 (9%) 43 (9%) 103 (9%)
6 No neurodev. conditions
VSD/other
No congenital anomalies
LOS <1 mo
2898 1880 4778 88 (3%) 45 (2%) 133 (3%)

We list the patient characteristics that define each group in terms of combinations of ≥1 of the following: absence/presence of neurodevelopmental (neurodev.) condition; absence/presence of congenital anomaly; low‐risk/high‐risk primary cardiac diagnosis; index length of stay >1 or <1 month. For each group, the number of patients and occurrence of adverse events in the development, test, and overall data set are provided. For patient group 3, figures are also provided for the 2 subcategories of primary cardiac diagnosis within the high‐risk group, namely hypoplastic left heart syndrome (HLHS) or functionally univentricular heart (UVH)/pulmonary atresia with intact ventricular septum (PA+IVS). CART indicates classification and regression tree; LOS, length of stay (index admission).